Search

for
Search:

GlossaryBrepocitinib

medication that inhibits enzymes involved in inflammation

Brepocitinib is a medication that inhibits certain enzymes known as Janus kinases (JAKs) and tyrosine kinase 2 (TYK2). These enzymes play a role in the inflammatory process, and by blocking them, Brepocitinib can help reduce inflammation and is being studied for the treatment of autoimmune conditions like alopecia areata, psoriasis, and other inflammatory diseases.

Related Terms

Learn

0 / 0 results

— no results

Research

5 / 57 results

research A Phase 2a Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of the Oral Janus Kinase Inhibitors Ritlecitinib and Brepocitinib in Alopecia Areata: 24-Week Results

138 citations, March 2021 in “Journal of the American Academy of Dermatology”

Ritlecitinib and brepocitinib effectively regrow hair in alopecia areata patients.

research Ritlecitinib And Brepocitinib Demonstrate Significant Improvement In Scalp Alopecia Areata Biomarkers

36 citations, December 2021 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology”

Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.

research Maintenance, Withdrawal, and Re-Treatment with Ritlecitinib and Brepocitinib in Patients with Alopecia Areata in a Single-Blind Extension of a Phase 2a Randomized Clinical Trial

20 citations, December 2021 in “Journal of the American Academy of Dermatology”

Continuous treatment with ritlecitinib and brepocitinib is needed to maintain hair regrowth in alopecia areata.

Comparative Efficacy and Safety of JAK Inhibitors in the Treatment of Moderate-to-Severe Alopecia Areata: A Systematic Review and Network Meta-Analysis

research Comparative Efficacy and Safety of JAK Inhibitors in the Treatment of Moderate-to-Severe Alopecia Areata: A Systematic Review and Network Meta-Analysis

April 2024 in “Frontiers in pharmacology”

Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.

Systematic Review of Newer Agents for the Management of Alopecia Areata in Adults: Janus Kinase Inhibitors, Biologics and Phosphodiesterase-4 Inhibitors

research Systematic Review of Newer Agents for the Management of Alopecia Areata in Adults: Janus Kinase Inhibitors, Biologics and Phosphodiesterase-4 Inhibitors

12 citations, December 2022 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology”

New oral treatments for adult hair loss show promise, especially JAK inhibitors, with mild side effects.

View more "brepocitinib" in research →

Community Join

0 / 0 results

— no results